EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.

Advertisements

Hematopoietic stem cell transplantation

Dao-Pei Lu May 2010, Shanghai Hematopoietic Stem Cell Transplantation (HSCT) in China (2010)

Bone Marrow Transplant in Oncology. Source Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate.

Module 1 Haematopoietic stem cell transplantation.

Transplantation of hematopoietic stem cells in pediatric oncology Vladivostok State Medical University Foreign languages department Vladivostok 2012 Scientific.

CLINICAL CODING FOR BM & PBSC TRANSPLANT PROCEDURES Dr Kim Orchard – Transplant Director Carol Hurlock – Data Manager Wessex Blood and Marrow Transplantation.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Allogeneic Stem Cell Transplantation: The Journey

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

The Middle East The The Arab World.

Acute Myeloid Leukemia

CHAPTER 1 BLOOD AND MARROW TRANSPLANTATION Editors: Dr Alan Teh Kee Hean Prof Dr Chan Lee Lee Expert Panel: Dr Alan Teh Kee Hean (co-chairperson) Prof.

Jordan Morocco Saudi Arabia Algeria Yemen Tunisia Oman Libya

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

What to label… Middle East pg. 164, Countries: Turkey, Syria, Lebanon, Israel, West Bank*, Gaza*, Egypt, Jordan, Saudi Arabia, Yemen, Oman, United.

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

HAPLOIDENTICAL STEM CELL TRANSPLANT

Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

University Hamburg Medical Center Dept of Stem Cell Transplantation

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

EBMT Activity Survey Teams Patients Transplants

Source: Freedom House, Freedom in the World 2006

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides INTRODUCTION: The Summary Slides are an annual report.

HS 4160 Critical Scientific Analysis

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Miguel-Angel Perales MD

LWP and lymphoma-related meetings and presentations

EBMT Activity Survey Teams Patients Transplants

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

إحصاءات أستخدام الوقت في المنطقة العربية ندى جعفر شعبة الإحصاء الأسكوا

What to label… Middle East North Africa

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and.

Figure 5 Number of AHSCT procedures for

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Biology of Blood and Marrow Transplantation

Kasiani C. Myers, Stella M. Davies

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Middle Eastern Nations & Locations

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Aplastic Anemia: Pathophysiology and Treatment

Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Countries and Capitals

Bridge to transplant following Bv+Bs regimen.

Eliane Gluckman Experimental Hematology

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Timing for HCT Consultation

Survival after HLA-Matched Sibling Donor HCT for ALL, Age ≥18 Years,

by Jan J. Cornelissen, and Didier Blaise

Presentation transcript:

EBMT Activity Survey 2016 679 Teams 39,313 Patients 43,636 Transplants 49 Countries For internal use only. For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch

EBMT Activity Survey in 2016: Patient and transplant numbers Allogeneic HSCT Autologous Total 1st allo/1st auto HSCT Additional HSCT TOTAL Teams: 679 (of 707) Countries reporting: 49 16,507 1,134 17,641 22,806 3,189 25,995 39,313 4,323 43,636 Indication

EBMT Activity Survey in 2016: Donor type and stem cell source: all transplants PBSC HLA-id sibling Haplo-identical Other family Syngeneic Unrelated Allogeneic Autologous 1,432 693 122 n.a. 1,452 3,699 98 5,977 2,306 341 24 8,993 17,641 25,995 Total 4,503 1,613 214 7,151 13,481 25,896 Donor type Stem Cell Source Cord 42 5 390 437 1

EBMT Activity Survey 2016: Main indications Allogeneic 1st HSCT Autologous Total Leukemia Lymphoma Plasma cell disorder Solid tumor Non-malignant disorders Bone marrow failure Other Total Patients 12,116 1,648 463 33 2,087 894 160 16,507 464 8,543 11,931 1,483 372 5 13 22,806 12,580 10,191 12,394 1,516 2,459 899 173 39,313 Indication

Allogeneic HSCT in Europe 2016 1st HSCT (early AML 21%, advanced AML 11%, transformed AML 6%) J.R. Passweg et al, Bone Marrow Transplantation, Jan 2018

Autologous HSCT in Europe 2016 1st HSCT J.R. Passweg et al, Bone Marrow Transplantation, Jan 2018

HSCT Activity in Europe 1990-2016: Transplant type 1st HSCT 58% 42% J.R. Passweg et al, Bone Marrow Transplantation, Jan 2018

HSCT Activity in Europe 1990-2016: donor origin: 1st. HSCT J.R. Passweg et al, Bone Marrow Transplantation , Jan 2018

HSCT Activity in Europe 1990-2016: Main indications: allogeneic 1st HSCT Activity in Europe 1990-2016: Main indications: allogeneic 1st. HSCT

HSCT Activity in Europe 1990-2016: Main indications: autologous 1st HSCT Activity in Europe 1990-2016: Main indications: autologous 1st. HSCT

HSCT - rates in Europe 2016 N. allogeneic transplants 0 or no report 1 - 100 101 - 150 151 – 200 201 – 300 > 300 Algeria, Iran, Iraq, Jordan, Kazakhstan, Lebanon, South Africa, Tunisia Saudi Arabia Israel N. allogeneic transplants per 10 million inhabitants J.R. Passweg et al, Bone Marrow Transplantation, Jan 2018

HSCT - rates in Europe 2016 N. autologous transplants per 10 million inhabitants 0 or no report 1 - 100 101 - 300 301 – 400 401 – 500 > 500 Algeria, Iran, Iraq, Jordan, Kazakhstan, Lebanon, Saudi Arabia, South Africa, Tunisia Israel J.R. Passweg et al, Bone Marrow Transplantation, Jan 2018